BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Profit Margin

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s profit margin stands at -43.06% as of June 2026. That compares with 1.96% in the prior-year period — down 2295.8% year over year. That is below the Healthcare sector average of 10.58%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. reported -43.06% in profit margin versus 1.96% a year earlier — a 2295.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. sits lower the Healthcare benchmark (10.58%) with a profit margin of -43.06%. That is roughly 506.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -43.06% for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s profit margin evolved across reporting periods, while the comparison chart places BML.WA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.